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Background: Survival of metastatic colorectal cancer (mCRC) patients has improved,
but mainly for trial patients. New predictive and prognostic biomarkers validated in
the general mCRC population are needed. Caudal-type homeobox 2 (CDX2) is an
intestine-specific transcription factor with potential prognostic and predictive effect, but
the importance in mCRC has not been fully investigated.
Methods: Immunohistochemistry analysis of CDX2 was performed in a Scandinavian
population-based cohort of mCRC (n = 796). Frequency, clinical and tumor
characteristics, response rate, progression-free survival, and overall survival (OS)
were estimated.
Results: Loss of CDX2 expression was found in 87 (19%) of 452 stained cases, in 53%
if BRAF mutated (BRAFmut) and in 9% if KRAS mutated (KRASmut). CDX2 loss was
associated with microsatellite instability, BRAFmut, and poor differentiation and inversely
associated with KRASmut. Patients with CDX2 loss received less first-line (53 vs. 64%,
p = 0.050) and second-line (23 vs. 39%, p = 0.006) chemotherapy and secondary
surgery (1 vs. 9%, p = 0.019). Median progression-free survival and OS for patients
given first-line combination chemotherapy was 4 and 10 months if CDX2 loss vs. 9
and 24 months if CDX2 expressed (p = 0.001, p < 0.001). Immediate progression
on first-line combination chemotherapy was seen in 35% of patients with CDX2 loss
vs. 10% if CDX2 expressed (p = 0.003). Median OS in patients with BRAFmut or
KRASmut and CDX2 expressed in tumor (both 21 months) was comparable to wild-type
patients (27 months). However, if CDX2 loss, median OS was only 8 and 11 months
in BRAFmut and KRASmut cases, respectively, and 10 months in double wild-type
patients. In multivariate analysis, CDX2 loss (hazard ratio: 1.50, p= 0.027) and BRAFmut
(hazard ratio: 1.62, p = 0.012) were independent poor prognostic markers for OS.
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Conclusion: In a population-based cohort of mCRC patients, CDX2 loss is an
independent poor prognostic marker. Expression of CDX2 defines a new subgroup of
BRAFmut cases with a much better prognosis. Loss of CDX2 defines a small group of
KRASmut cases with a worse prognosis. Patients with CDX2 loss receive less palliative
chemotherapy with less benefit and rarely reach secondary surgery.
Keywords: caudal type homeobox transcription factor, CDX2, colorectal cancer, metastatic disease, stage 4
colorectal cancer, prognosis, population based
INTRODUCTION
Colorectal cancer (CRC) is one of the major cancer types
worldwide. Globally, there are 1.4 million new cases and
0.7 million deaths in 2012 (1, 2). Approximately 25% of
patients present with metastatic CRC (mCRC) at diagnosis,
and another 20% will eventually develop metastasis. Despite
progress over the past decades, with median overall survival
(OS) up to 30 months in clinical trials, prognosis for patients
in population-based cohorts is still poor with a median OS
of 10–15 months (3, 4). Patients included in clinical trials are
highly selected with, for instance, better performance status,
younger age, and less or no comorbidity, and cannot be
compared to the general mCRC patients. There is a need for
predictive and prognostic markers validated in population-based
cohorts to guide treatment selection and improve survival for
mCRC patients.
Caudal-type homeobox 2 (CDX2) is an intestine-specific
transcription factor and one of the most sensitive and specific
markers of intestinal differentiation (5). Immunohistochemistry
(IHC) analysis for CDX2 is implemented in the clinical
diagnostics as a biomarker for intestinal differentiation in tumors
of unknown origin. It is deregulated in a subset of patients
with CRC, and downregulation has been associated with poor
prognosis (6–13). Loss of CDX2 expression has also been
associated with other poor prognostic features such as advanced
stages, poor differentiation, BRAF mutation (BRAFmut), and
microsatellite instability (MSI) (12, 14, 15). The negative
prognostic effect of CDX2 could therefore be related to the
known associations between these features and poor survival. No
previous studies have fully explored if the negative prognostic
effect of CDX2 loss in mCRC could be confounded by these
associations. Two recent retrospective studies have reported
CDX2 loss as a predictive biomarker for treatment benefit of
chemotherapy in stage II (7) and stage III (8) CRC. This has so
far not been demonstrated in mCRC (8, 9, 11). Recently, CDX2
loss was reported to be an independent negative prognostic
marker in mCRC patients undergoing curative liver metastasis
resection, indicating CDX2 loss as a potential biomarker to
identify patients with limited benefit from surgery (11). It is
therefore important to know the proper frequency of CDX2 loss
and its relations to outcome in unselected mCRC patients. The
aim of this study was to determine the prevalence, prognostic,
and predictive effect of CDX2 loss in unselected patients of




A prospectively collected cohort was established of all non-
resectable mCRC patients referred to the oncology units of three
regional hospitals in Scandinavia: Odense University Hospital
(Denmark) (n = 325), Uppsala University Hospital (Sweden) (n
= 155), and Haukeland University Hospital (Norway) (n = 316)
during 2003–2006 with last follow-up in 2014. These hospitals
cover all oncology treatment in their region. Cases not referred
in the region were identified through the national (Norway and
Sweden) and regional (Denmark) cancer registries (n = 49). The
cohort consists of 796 patients (Figure 1).
Tissue Retrieval and Tissue Microarray
Generation
Paraffin-embedded tissue blocks were retrieved from the primary
tumor in the majority of cases or from a metastatic lesion
(six cases), and corresponding hematoxylin–eosin stained glass
slides were examined. Tissue microarray (TMA) generation had
been performed previously in 460 (58%) cases (16) according to
standards used in the Human Protein Atlas (17), with two 1-mm
diameter tumor cores extracted per patient. TMA was generated
from tissue blocks from surgical resection of primary tumor in
419 of 460 (91%) TMA cases, the remaining 41 from biopsies (35
cases from primary tumor and 6 cases from metastatic lesion).
Tumor Analyses
Results on gene analysis of KRAS, BRAF, and MSI in BRAFmut
tumors and IHC analysis on BRAF and MMR were available
and performed as described previously (16, 18). IHC for CDX2
was performed for all patients included in the TMA cohort (n
= 460) using a mouse-monoclonal antibody, #NCL-CDX2, from
Leica Biosystems (formerly Novocastra), diluted 1:50. Automated
IHC was performed using an Autostainer 480 instrument
(Thermo Fischer Scientific, Waltham, MA, United States), with
diaminobenzidine (Thermo Fisher Scientific) as chromogen.
High-resolution images of the IHC staining were obtained by
scanning with an Aperio AT2 slide scanner (Aperio, Vista,
CA, United States) at 200× magnification. Semiquantitative
assessment of immunoreactivity in all tumor cells was assessed
independently by two pathologists (AD, FP) without knowledge
of clinicopathological data. Annotation discrepancies were re-
evaluated to reach consensus. Immunoreactivity was scored for
nucleus on a four-tier intensity scale (1 = negative, 2 = weak,
3 = moderate, or 4 = strong), and the estimated fraction of
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FIGURE 1 | Flow chart describing collection of tumor blocks, tissue
microarray (TMA), and availability of CDX2 status in a population-based
Scandinavian cohort of metastatic colorectal cancer.
stained tumor cells was denoted as 1 (0–1%), 2 (2–10%), 3
(11–25%), 4 (26–50%), 5 (51–75%), and 6 (>75%) (Figure 2).
Loss of CDX2 expression (CDX2 loss) was defined as tumors
with nuclear fraction staining <10% regardless of intensity, as
recommended in the interpretation of IHC of tumor markers
in CRC (19). This cutoff was chosen according to previous
literature, and the distribution of expression across the cohort.
CDX2 expression was defined as tumors with nuclear fraction
staining>10% regardless of intensity. CDX2 status was evaluable
in 452 cases (Figure 1).
Statistics
Exact chi-square test was used for group comparisons. Multiple
binary logistic regression was used for dichotomous outcome
variables, and results are reported as odds ratios (ORs) with
95% confidence intervals (CIs). OS was the interval from the
date of metastatic disease to the date of death and censored
if the patient was alive on February 4th, 2014. Progression-
free survival (PFS) was the interval from the date of first
administration of chemotherapy to the date of progression
(on CT scan) or death and censored if the patient was alive
without progression on February 4th, 2014. OS and PFS were
analyzed using the Kaplan–Meier method with log rank test and
Cox multiple regression. Cox regression was performed with
backward stepwise selection of covariates to the final model.
At the first step, we included all relevant covariates. From this
model, we removed the variable with the largest p-value. In the
second step, we removed the covariate with largest p > 0.05
among the remaining variables from the first step. The process
continued until all remaining variables were significant at level
0.05, and a final model was obtained. Results are reported as
hazard ratios (HRs) and 95% CIs. All analyses were performed
with the statistical program SPSS v22. All statistical tests were
two-tailed using 5% significance level.
RESULTS
Study Population
Of the 796 patients included, 460 patients had TMA generated;
reasons for no TMA were too small biopsies with no resection
of primary tumor performed (n = 239) and missing or
no cancer tissue (n = 97) (Figure 1). Cases with lacking
TMA was evenly distributed between the three regions of
inclusion (45% from Haukeland, 36% from Uppsala, and 43%
from Odense University Hospital, p = 0.190). For patients
with CDX2 status available, median OS was 11 months (9.4,
12.6) for all patients (n = 452), 18 months (15.0, 21.0)
if given first-line chemotherapy (n = 281) and 21 months
(17.1, 24.9) if given first-line combination chemotherapy (n =
217). As first-line treatment, 52 patients received irinotecan-
based and 168 oxaliplatin-based combination chemotherapy,
and 57 received 5-fluorouracil monotherapy. Twenty-one had
bevacizumab and 20 had cetuximab combination treatment.
Combination chemotherapy was mainly doublet; only three
patients received triplet chemotherapy. There was no significant
difference in treatment schedules given between patients with
loss or expression of CDX2 (Table S1). For patients with CDX2
status available, 21% had a BRAF V600E mutation (BRAFmut),
41% a KRAS mutation (KRASmut), 8% were MSI high (MSI-
H), and 38% double (KRAS and BRAF) wild-type tumor
(Table 1, Figure 3A).
Patient Characteristics and Treatment
Eighty-seven (19%) of 452 patients had CDX2 loss (Figure 3A).
Frequency of CDX2 loss was similar (20%) among the
subgroup of elderly patients (>75 years). In patients with
MSI-H, BRAFmut and KRASmut tumors, 58, 53, and 9%
had CDX2 loss, respectively. A Venn diagram (Figure 3A)
illustrates the frequency of CDX2 loss, MSI-H, BRAFmut, and
KRASmut, and their interrelations. CDX2 loss was associated
with right-sided primary tumor, poor differentiation, MSI-H,
BRAFmut, and KRAS wild type (KRASwt) (Table 1, Figure 3B).
In subgroup analyses, cases with CDX2 loss were mostly
BRAFmut/MSS (42%), and cases with CDX2 expression were
mostly BRAFwt/MSS (87%) (Figure 3C). Patients with CDX2
loss had less often lung metastases and liver-only disease, but
more often distant lymph node metastases (Table 1). In multiple
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FIGURE 2 | Immunohistochemical staining images of caudal-type homeobox 2 (CDX2) on tumor tissue microarray in a population-based Scandinavian cohort of
metastatic colorectal cancer patients. (A) Strong staining in all cells. (B) Completely negative staining.
logistic regression, BRAFmut and poor differentiation were
significantly correlated to CDX2 loss (Table S2). Patients with
CDX2 loss received less first- (53 vs. 64%, p = 0.050) and
second-line chemotherapy (23 vs. 39%, p= 0.006) and rarely had
secondary surgery (1 vs. 9%, p= 0.019) compared to patients with
CDX2 expressed.
Survival and Response
Median OS in the whole cohort (untreated and treated with
chemotherapy) was 6 months if tumor had CDX2 loss and
13 months if tumor showed CDX2 expression (p < 0.001).
For patients given first-line chemotherapy, median OS was
11 months if CDX2 loss (n = 46) and 21 months if CDX2
expressed (n = 235) (p < 0.001). For patients given first-line
combination chemotherapy, median OS was 10 months if CDX2
loss and 24 months if CDX2 expressed (p < 0.001) (Figure 4).
Median PFS after first-line chemotherapy was 5 vs. 8 months
(p = 0.003) in patients with CDX2 loss vs. expression and
4 vs. 9 months (p = 0.001) if given first-line combination
chemotherapy (Figure 4). We did not observe any survival
benefit of combination chemotherapy compared to monotherapy
in first-line treatment of patients with tumors demonstrating
CDX2 loss (median OS 10 vs. 12 months, p = 0.979 and median
PFS 5 vs. 4 months, p = 0.742), but this was evident in patients
with tumors demonstrating CDX2 expression (median OS 12
vs. 24 months, p < 0.001 and median PFS 5 vs. 9 months p
< 0.001) (Figure 5). For patients given first-line combination
chemotherapy with response registered (n = 194 of 217),
objective response rate was 35% if the tumor showed CDX2 loss
and 49% if CDX2 was expressed. Immediate disease progression
was seen in 35% of patients with CDX2 loss compared to 10%
with CDX2 expressed (Table S3, Figure 5E).
In further subgroup survival analyses, we selected patients
given first-line combination chemotherapy to eradicate potential
treatment selection bias (Figure 4D). In patients with double
(KRAS and BRAF) wild-type tumor, median OS was 10 months if
CDX2 loss (n = 10) compared to 27 months if CDX2 expressed
(n = 77) (p = 0.576). Patients with KRASmut tumor had
median OS of 11 months if CDX2 loss (n = 4) compared to
21 months if CDX2 expressed (n = 83) (p = 0.007). Patients
with BRAFmut tumors had median OS of 8 months if CDX2
loss (n = 18) compared to 21 months if CDX2 expressed
(n = 21) (p = 0.008). Owing to selection of patients treated
with combination chemotherapy, we had few patients in some
subgroups, particularly of cases with KRASmut and CDX2 loss.
However, when analyzing all KRASmut cases, regardless of
treatment, median OS was only 2 months if CDX2 loss (n =
16) compared to 13 months if CDX2 expressed (n = 163) (p
< 0.001). The negative prognostic effect of CDX2 loss was also
significant when analyzing all BRAFmut cases, with 6 months
median OS if CDX2 loss (n = 51) compared to 10 months if
CDX2 expressed (n = 45) (p = 0.008) (Figure S1). In patients
treated with first-line chemotherapy, the negative prognostic
potential of CDX2 loss was seen regardless of BRAF, KRAS, and
MSI status (Figure S2), however with few patients in some of the
subgroups. CDX2 loss was a poor prognostic marker regardless
of tumor side (left-sided 12 vs. 25 months and right-sided 8 vs.
22 months median OS, p < 0.001) and tumor grade (poorly
differentiated 6 vs. 20 months, p < 0.001 and well/moderately
differentiated 14 vs. 25 months median OS, p= 0.002) in patients
treated with first-line combination chemotherapy. Elderly given
first-line chemotherapy had a median OS of 9 months if CDX2
loss compared to 15 months if CDX2 expressed (p= 0.048).
In multiple Cox regression analyses, with known prognostic
factors for mCRC survival, both CDX2 loss and BRAFmut
(among others) were statistically significant associated with
reduced OS. CDX2 loss, MSI-H, BRAFmut, and KRASmut
(among others) with shorter PFS (Table 2).
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TABLE 1 | Patient characteristics according to caudal-type homeobox 2 status in
a population-based cohort of metastatic colorectal cancer with CDX2 status




Missing CDX2– CDX2+ CDX2– vs.
CDX2+
p-value
Total number (%) 452 87 (19) 365 (81)









Age > 75 years, n (%) 155 (34) 31 (36) 124 (34) 0.802
Female, n (%) 229 (51) 50 (58) 179 (49) 0.189
PS WHO > 1, n (%) 152 (34) 37 (43) 115 (32) 0.058
Right sided, n (%) 177 (40) 7 52 (60) 125 (35) <0.001
Liver metastases, n (%) 287 (64) 49 (56) 238 (65) 0.137
Liver only, n (%) 118 (26) 14 (16) 104 (29) 0.018
Lung metastases, n (%) 113 (25) 14 (16) 99 (27) 0.038
Lymph node
metastases, n (%)
131 (29) 37 (43) 94 (26) 0.003
Peritoneal metastases,
n (%)
88 (20) 23 (26) 65 (18) 0.072
>1 metastatic site, n
(%)
262 (58) 55 (63) 207 (57) 0.280
Synchronous
metastases, n (%)
244 (54) 54 (62) 190 (52) 0.095
ALP high, n (%) 222 (56) 55 43 (60) 179 (55) 0.513
Primary tumor
resected, n (%)
414 (92) 80 (92) 331 (92) 1.000
Tumor grade 1, n (%) 55 (13) 15 7 (8) 48 (14) <0.001
2, n (%) 288 (66) 39 (47) 249 (70)
3, n (%) 94 (22) 37 (45) 57 (16)
KRAS mutation, n (%) 179 (41) 15 16 (19) 163 (46) <0.001
BRAF mutation, n (%) 96 (21) 9 51 (59) 45 (12) <0.001
Double wild type, n (%) 164 (38) 15 18 (21) 146 (41) 0.001
MSI-H, n (%) 35 (8) 11 21 (26) 14 (4) <0.001
BRAFmut/MSI-H, n (%) 30 (7) 16 18 (23) 12 (3) <0.001
BRAFmut/MSS, n (%) 66 (15) 33 (42) 33 (9)
BRAFwt/MSI-H, n (%) 5 (1) 3 (4) 2 (1)
BRAFwt/MSS, n (%) 336 (77) 25 (32) 311 (87)
Curative metastasis
surgery, n (%)
33 (7) 1 1 (1) 32 (9) 0.019
First-line
chemotherapy, n (%)
281 (62) 46 (53) 235 (64) 0.050
Combination, n (%) 217 (77) 34 (74) 183 (78) 0.567
Monotherapy, n (%) 64 (23) 12 (26) 52 (22)
Second-line
chemotherapy, n (%)
162 (36) 1 20 (23) 142 (39) 0.006
Third-line
chemotherapy, n (%)
72 (16) 1 2 (2) 70 (19) <0.001
BSC only, n (%) 170 (38) 41 (47) 129 (35) 0.049
CDX2–, CDX2 loss; CDX2+, CDX2 expression; MSI-H, microsatellite instable high;
MSS, microsatellite stable; PS ECOG, performance status score developed by Eastern
Cooperative Oncology Group; Right sided, site of colon cancer in ascending colon and
transversum; Left sided, site of colon cancer in descending colon, sigmoid, and rectum;
Metastases, at time of diagnosis of metastatic disease; Synchronous metastases, within
6 months after initial diagnose; ALP high, alkaline phosphatase >105 U/L; Double wild
type, both BRAF and KRAS wild type; BRAFmut, BRAF mutated; BRAFwt, BRAF wild
type; BSC, best supportive care; p-value, chi-square test except for age (t-test).
*Percentage is calculated without missing values. Owing to rounding, not all percentages
are 100 in total.
DISCUSSION
This is the largest study of incidence of CDX2 loss and its
correlation to treatment and survival in a population-based
cohort of mCRC and the first study that also corrects for
the prognostic markers MSI, BRAF, and KRAS status in the
analyses. The generally poor survival in our cohort is comparable
to Scandinavian cancer registries (3) and the American SEER
database during the same time period (20), reflecting our
unselected population of mCRC. A recent study confirms the
low median OS of mCRC patients in the general population
compared to phase III trial results (4). Our real-world data shows
that mCRC patients who have non-resectable metastatic disease
with CDX2 loss have a worse prognosis, receive less first- and
second-line chemotherapy with less benefit and rarely receive
secondary surgery.
The incidence of CDX2 loss was 19%, comparable to previous
published results on stage IV CRC patients in population-based
cohort studies (8, 15). Others have reported lower frequency of
CDX2 loss, but most of these studies have very few patients with
stage IV disease (21, 22). Two recent mCRC studies showed only
3–6% CDX2 loss, probably reflecting the selection of patients
with better prognosis into clinical trials (10) and patients treated
at the Mayo Clinic (9) compared to our population-based cohort.
CDX2 loss was significantly associated with poor prognostic
markers such as MSI-H, BRAFmut, right-sided tumors, and poor
differentiation, in accordance with previous reports (8, 12, 15).
In our study, we demonstrate that CDX2 loss is an independent
negative prognostic tumor marker, even after correcting for these
known prognostic factors.
BRAFmut is considered the clinically most important negative
prognostic marker in mCRC (23, 24). Both BRAFmut and
KRASmut are poor prognostic markers after liver (25–27)
and lung surgery (28) and after cytoreductive surgery with
hyperthermic intraperitoneal chemotherapy (29). BRAFmut has
therefore been suggested to be one of the factors to consider
before metastatic surgery. However, in the clinic, it has been
observed that some patients with BRAFmut tumors have a
relatively long survival, despite the mutational status. This
was recently explored in study of 395 BRAFmut mCRCs,
where clinical prognostic markers defined three vastly different
prognostic groups (30). Our study may, at least in part, explain
this as it demonstrates that CDX2 expression defines a new
prognostic subgroup in patients with BRAFmut (53%) with a
much better prognosis, comparable to wild-type patients. We
also verify that CDX2 loss is a poor prognostic marker in
this subgroup, as demonstrated in a very recently published
study (31).
Loss of CDX2 expression also defines a smaller group (9%)
of KRASmut cases with a worse prognosis, but this needs to be
validated due to few cases in our cohort. These results could
have clinical implications when considering treatment strategies
for such patients, and further studies of patients undergoing
curative metastasis surgery should evaluate if CDX2 status could
impact on the negative prognosis of BRAFmut and KRASmut.
CDX2 loss has also recently been demonstrated as a negative
prognostic marker after liver metastasectomy, but this study did
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FIGURE 3 | Distribution of different molecular markers in a population-based Scandinavian cohort of metastatic colorectal cancer. (A) Frequency (%) of BRAF,
microsatellite instability (MSI), KRAS, and caudal-type homeobox 2 (CDX2) status and their interrelations. (B) Frequency (%) of BRAF, MSI-H, and KRAS mutations in
tumors with CDX2 loss and CDX2 expression. (C) BRAF/MSI subgroups in tumors with CDX2 loss and CDX2 expression. KRASmut, KRAS mutation; BRAFmut, BRAF
mutation; MSI-H, microsatellite instable high; MSS, microsatellite stable; double wild type, wild-type KRAS and BRAF; CDX2–, CDX2 loss; CDX2+, CDX2 expression.
not correct for KRAS or BRAF mutation status (11). According
to our results, it is a reason to believe that CDX2 loss could
be a negative prognostic marker for these patients regardless of
mutational status, but due to small numbers in our subgroup
analysis, particularly in cases with KRASmut and CDX2 loss, this
needs to be verified in larger study cohorts.
Recent retrospective studies of stage II–III CRC report
CDX2 loss as a potential predictor of benefit from adjuvant
chemotherapy (7, 8). In the metastatic situation, the predictive
effect of CDX2 loss seems rather to be the opposite (8, 9, 11).
In our study, patients with CDX2 loss had poorer survival
and response to chemotherapy with more often immediate
disease progression on first-line combination chemotherapy,
shorter PFS, and few made it to second-line treatment or
secondary surgery. This might indicate that patients with
CDX2 loss should have a different treatment regimen. An
intuitive approach would be, as for BRAFmut tumors, to
use triple combination therapy (32). Only a few patients
were included in our subgroup analyses, however, no
increased OS benefit of using doublet chemotherapy vs.
monotherapy was seen in patients with CDX2 loss. It is
therefore not sure that these patients will benefit from a
more intensified chemotherapy regimen. Further studies on
new treatment regimens in this subgroup of patients are
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FIGURE 4 | Median overall survival (OS) and progression-free survival (PFS) in a population-based Scandinavian cohort of metastatic colorectal cancer according to
tumor molecular alterations. Kaplan–Meier curves were calculated with log-rank test for p value and univariate Cox regression for HR and 95% CI. (A) Median OS for
all patients according to CDX2 status. (B) Median OS according to CDX2 status for patients given first-line combination chemotherapy. (C) Median PFS according to
(Continued)
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FIGURE 4 | CDX2 status for patients given first-line combination chemotherapy. (D) Median OS according to tumor molecular alterations in patients given first-line
combination chemotherapy: double wild type 26 months (n = 88, e = 80), KRASmut/CDX2 expressed 21 months (n = 82, e = 77), BRAFmut/CDX2 expressed 21
months (n = 21, e = 20), KRASmut/CDX2 loss 11 months (n = 4, e = 4), BRAFmut/CDX2 loss 8 months (n = 18, e = 18). (E) Median PFS according to tumor
molecular alterations in patients given first-line combination chemotherapy: double wild type 10 months (n = 88, e = 85), KRASmut/CDX2 expressed 8 months (n =
83, e = 78), BRAFmut/CDX2 expressed 9 months (n = 21, e = 20), KRASmut/CDX2 loss 2 months (n = 4, e = 4), BRAFmut/CDX2 loss 4 months (n = 18, e = 18).
n, number; e, events; double wild type: KRAS and BRAF wild type; BRAFmut, BRAF mutation; KRASmut, KRAS mutation; HR, hazard ratio; CI, confidence interval;
CDX2–, CDX2 loss; CDX2+, CDX2 expression.
FIGURE 5 | Median overall survival (OS), progression-free survival (PFS), and response rate if given first-line mono- or combination chemotherapy according to tumor
CDX2 status in a population-based Scandinavian cohort of metastatic colorectal cancer. Kaplan–Meier curves were calculated with log-rank test for p-value and
univariate Cox regression for HR and 95% CI. (A) Median OS in patients with CDX2 loss. (B) Median OS in patients with CDX2 expressed. (C) Median PFS in patients
with CDX2 loss. (D) Median PFS in patients with CDX2 expressed. (E) Response rate (%) after first-line combination chemotherapy according to CDX2 status. n,
number; e, events; HR, hazard ratio; CI, confidence interval; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
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TABLE 2 | Results from multiple Cox regression of overall survival and
progression-free survival in a population-based Scandinavian cohort of metastatic
colorectal cancer patients.
Overall survival*




(n = 245, e = 235)
Variable HR 95% CI p-value HR 95% CI p-value
Female 0.85 (0.68, 1.03) 0.148 0.94 (0.72, 1.23) 0.655
AGE >75 years 1.04 (0.74, 1.46) 0.844 1.59 (1.02, 2.46) 0.039
PS WHO > 1 1.78 (1.36, 2.34) <0.001 2.02 (1.39, 2.93) <0.001
Right-sided
tumor
1.06 (0.82, 1.37) 0.662 0.75 (0.55, 1.04) 0.081
Tumor grade 3 1.66 (1.22, 2.25) 0.001 1.55 (1.08, 2.23) 0.019
Primary tumor
resected
1.14 (0.65, 2.00) 0.657 1.65 (0.92, 2.97) 0.095
Synchronous
metastases
0.70 (0.55, 0.88) 0.002 0.75 (0.56, 1.01) 0.056
>1 organ
metastases
1.34 (1.02, 1.76) 0.038 1.47 (1.00, 2.15) 0.049




0.32 (0.20, 0.52) <0.001 0.38 (0.24, 0.62) <0.001
ALP high 1.98 (1.55, 2.54) <0.001 1.55 (1.15, 2.09) 0.004
First-line
chemotherapy
0.37 (0.25, 0.53) <0.001 n.i.
MSI-H 1.38 (0.83, 2.30) 0.212 2.08 (1.06, 4.08) 0.032
KRAS mutation 1.25 (0.97, 1.62) 0.088 1.62 (1.17, 2.23) 0.003
BRAF mutation 1.62 (1.11, 2.35) 0.012 1.63 (1.04, 2.55) 0.032
CDX2 loss 1.50 (1.05, 2.15) 0.027 1.54 (1.00, 2.35) 0.049
n, number of patients; e, number of events; HR, hazard ratio; CI, confidence interval;
p value, from likelihood ratio test; PS ECOG, performance status score developed
by Eastern Cooperative Oncology Group; Right-sided tumor, site of colon cancer in
ascending colon and transversum; Synchronous metastases, within 6 months after initial
diagnose; ALP high, alkaline phosphatase > 105 U/L; MSI-H, microsatellite instable high;
n.i., not included.
*CEA > 4 and LDH high was also statistically significant when included in the multiple
regression model but were excluded from the analysis due to many missing values.
clearly warranted, as they might need a completely different
treatment approach.
The recently updated National Comprehensive Cancer
Network guidelines recommend addition of BRAF inhibitors
to standard second-line treatment in patients with BRAFmut
tumors (33). Encouraging data have been published on EGFR-,
BRAF-, and MEK-inhibitor combination treatment of patients
with BRAFmut mCRC (34). However, far from all patients
benefit substantially from this treatment, and it could be
relevant to study if the benefit of this regimen depends on
CDX2 status. Tumor MSI status is used as a predictive marker
for immunotherapy effect in mCRC patients, and checkpoint
inhibitors are currently recommended as second-line treatment
for patients with MSI-H tumor according to the National
Comprehensive Cancer Network guidelines (33). Since CDX2
loss is associated withMSI-H status and both are poor prognostic
markers with poor response to standard chemotherapy inmCRC,
future studies should also evaluate if the effect of checkpoint
inhibitors may vary according to CDX2 status.
LIMITATIONS
As this is a population-based study, patients with both poorer
performance status, older age, and comorbidity are included, and
results are therefore difficult to compare with patients included in
phase III clinical trials. It is also difficult to assess the predictive
effect of CDX2 in our cohort, as patients not given chemotherapy
are in the worst prognostic group. Although this is a population-
based study, we know that patients who did not have tumor
tissue available to perform TMA, and therefore not included in
the biomarker analysis, have a particularly poor prognosis (16).
To remove treatment selection bias, we chose to select patients
treated with first-line and first-line combination chemotherapy
for further subgroup survival analyses. In some of the biomarker
subgroup analyses, we therefore had few patients, which could
affect the results. Our molecular analyses were mainly performed
on tissue from primary tumor and not the metastatic site;
however, most studies of tumor molecular alterations show
high concordance between primary tumor and metastases (35).
Furthermore, the evaluation of CDX2 was based on IHC analysis
on small TMA sections. Although two samples were taken from
each tumor, the possibility of intratumoral heterogeneity cannot
be excluded. Finally, the studied patient cohort is more than 10
years old. Treatment options for mCRC patients has, however,
not changed much during this time period, although today we
treat more fit patients with intensified chemotherapy regimens
as well as metastasectomy. There are also recent data from a
Dutch population-based synchronic mCRC series reporting no
difference in median OS during the past 10 years (4).
CONCLUSIONS
In an unselected cohort of mCRC, CDX2 loss is an independent
negative prognostic marker for survival. CDX2 loss indicates
poor response and less survival benefits from standard
chemotherapy in the metastatic situation, and effort is needed in
finding new treatment regimens for this subgroup of patients.
Expression of CDX2 defines a new subgroup of BRAFmut
cases with a much better prognosis. Loss of CDX 2 also defines
a smaller group of KRASmut cases with a worse prognosis.
CDX2 status may therefore be clinically relevant for a choice of
treatment strategy.
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